Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4108594 | 0.99 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13800334 | 0.92 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13800763 | 0.92 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR7MAOB | |
| SCHEMBL13813567 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13813623 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR7MAOB | |
| Hydrochloric Acid SCHEMBL4132545 | 0.91 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13800632 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13813592 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TGFBR1ACVR1 | |
| SCHEMBL13800650 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR7MAOB | |
| SCHEMBL13800736 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR7MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | SLC6A2 4192/4885SLC6A4 3416/4885SLC6A3 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.